ライフサイエンスコーパス: uveitis

1 imab in patients with chronic non-infectious uveitis.

2 rgery can be safe and effective in eyes with uveitis.

3 ts showed negative laboratory assessment for uveitis.

4 inal endothelial cells during non-infectious uveitis.

5 mous, Rip2-independent mechanism for Nod2 in uveitis.

6 ng therapeutic effect of targeting IL-17A in uveitis.

7 e course of inflammation in a mouse model of uveitis.

8 of these patients also showing retinitis or uveitis.

9 similar occurrence of sunset glow fundus and uveitis.

10 ma surgery after the resolved episode of the uveitis.

11 echniques were less likely to report chronic uveitis.

12 n driving chronic inflammation in autoimmune uveitis.

13 obia are the most frequent onset of anterior uveitis.

14 ified in 164 patients with posterior segment uveitis.

15 e, an inflammatory disorder characterized by uveitis.

16 and did not have alternative etiologies for uveitis.

17 RB breakdown during non-infectious posterior uveitis.

18 e cell populations over time in experimental uveitis.

19 over follow-up in the setting of suppressed uveitis.

20 effective based on the anatomical subtype of uveitis.

21 synechiae and CME characterize RV-associated uveitis.

22 eitis is almost double than in those without uveitis.

23 189 patients in the analysis population had uveitis.

24 e treatment monitoring of eyes with anterior uveitis.

25 0.31 vs. 0.21; P = 0.025) than those without uveitis.

26 d suggest a potential therapeutic avenue for uveitis.

27 relapse activity compared with those without uveitis.

28 nts with uveitis compared with those without uveitis.

29 d amplify retinal inflammation in autoimmune uveitis.

30 aocular lens (IOL) implantation in eyes with uveitis.

31 oma patients with uveitis than those without uveitis.

32 neurologic, and musculoskeletal findings and uveitis.

33 ere used to better assess different types of uveitis.

34 firmation of the diagnosis of viral anterior uveitis.

35 s not previously linked to posterior segment uveitis.

36 mune uveitis (EAU), an animal model of human uveitis.

37 tcomes related to a history of noninfectious uveitis.

38 ger CC FDs than patients with other forms of uveitis.

39 uppression of Th17 immunity and experimental uveitis.

40 registered for QFT-G-positive patients with uveitis.

41 ics describing such lesions in patients with uveitis.

42 52 or 36.5%), followed by HLA-B27-associated uveitis (11/52, 21.1%), infectious uveitis (6/52, 11.5%)

43 Of all QFT-G-positive patients with uveitis, 17 patients had chest imaging changes suggestin

44 eitis (6/52, 11.5%), and juvenile idiopathic uveitis (4/52, 7.7%).

45 dication was more common among patients with uveitis (47/96 [49.0%]) compared with patients without u

46 2, 11.5%), tubulointerstitial nephritis with uveitis (6/52, 11.5%), and juvenile idiopathic uveitis (

47 ssociated uveitis (11/52, 21.1%), infectious uveitis (6/52, 11.5%), tubulointerstitial nephritis with

48 87%), female (92%), and had chronic anterior uveitis (65%).

49 7/96 [49.0%]) compared with patients without uveitis (78/338 [23.1%]).

50 kness and volume in eyes with acute anterior uveitis (AAU) using enhanced depth imaging-optical coher

51 437 among patients with more severe baseline uveitis (AC cell count >25).

52 on (aDelta: -0.024, P = 0.021), and incident uveitis activity in at least 1 eye (aDelta: -0.023, P =

53 Uveitis activity was assessed clinically and by ICGA.

54 on was found to be associated with decreased uveitis activity, as was sun exposure in those with vita

55 iated with cataract formation independent of uveitis activity.

56 ystemic (19% vs. 40%) and local (7% vs. 62%) uveitis adjunctive treatments were observed with FA inse

57 o [aHR], 0.61; 95% CI, 0.44-0.83), bilateral uveitis (aHR, 0.75; 95% CI, 0.59-0.96), prior cataract s

58 ening diseases like seasonal hyper-acute pan-uveitis also presented.

59 Though the association between uveitis and a positive QFT-G test might be coincidental,

60 orneal edema including a history of anterior uveitis and an anterior chamber glaucoma drainage device

61 Patient diagnoses of PVRL versus uveitis and associated aqueous or vitreous IL-6 and IL-1

62 Quantitative metrics were compared between uveitis and control eyes.

63 Uveitis and episcleritis are the most common ocular EIMs

64 on of expression of those receptors in human uveitis and healthy tissues suggests that infiltrating c

65 nd autoimmune diseases, including autoimmune uveitis and its animal model, EAU.

66 key mediators of autoimmune diseases such as uveitis and its animal model, experimental autoimmune uv

67 models achieved complete separation between uveitis and lymphoma in the aqueous data set.

68 ed between patients with active and inactive uveitis and population-based estimates of serum 25-hydro

69 Only patients with uveitis and presumed or biopsy-proven sarcoidosis (N = 1

70 Subjects: Patients with dual diagnoses of uveitis and presumed/biopsy-proven sarcoidosis.

71 examination of the right eye showed anterior uveitis and vitritis associated with large paravascular

72 6/12 was found in 12 of 135 eyes (8.9%) with uveitis, and 4 of 80 patients (5.0%) with JIA-U had bino

73 Six patients (43%) demonstrated intermediate uveitis, and 8 patients (57%) demonstrated panuveitis.

74 Angle recession, uveitis, and aphakia increased the odds of a nonresponse

75 Lower baseline IOP, angle recession, uveitis, and aphakia were associated with increased odds

76 on of uveitis, presence and degree of active uveitis, and concomitant use of other forms of corticost

77 ding eyes such as conjunctivitis, scleritis, uveitis, and corneal ulcer.

78 d eyelids, although marginal corneal ulcers, uveitis, and epibulbar masses have also been reported, a

79 e colitis, the arthritis related to anterior uveitis, and finally, somewhat controversially Behcet's

80 Presence of posterior synechiae, active uveitis, and use of topical corticosteroids at presentat

81 subjects with active noninfectious anterior uveitis (anterior chamber [AC] cell count >=11 cells) we

82 Uveitis are unrelated with IBD activity and they even pr

83 Adalimumab is clinically effective in uveitis associated with JIA; however, its cost effective

84 Drug retention rate of ADA in uveitis at 60 months was 54.28%, with a good safety prof

85 ified into 4 cohorts based on the history of uveitis at baseline and uveitis events during the observ

86 All patients demonstrated active uveitis at baseline, and 34 patients (41.5%) demonstrate

87 ission incidence included longer duration of uveitis at presentation (for 2 to 5 years vs. less than

88 The primary outcome was quiescence of uveitis before and after the switch.

89 Patients with a diagnosis of uveitis before the onset of JIA all developed cataract a

90 ticosteroid-sparing control of noninfectious uveitis, but there is uncertainty about which drug is mo

91 inal function in patients with noninfectious uveitis by using full-field electroretinography (ERG) an

92 tcome measurements currently used in chronic uveitis care fail to cover the full patient perspective.

93 Uveitis cases should be monitored carefully for IOP elev

94 Among uveitis cases, Vogt-Koyanagi-Harada syndrome (VKH) (odds

95 is uncommon, accounting for 2 to 14% of all uveitis cases, yet resulting in significant ocular morbi

96 patient history of autoimmune disease and/or uveitis, cataract surgery combined with another intraocu

97 e patients with otherwise unexplained severe uveitis cause had a beneficial response to antituberculo

98 hat 29% of patients referred to our tertiary uveitis center diagnosed as "idiopathic" had an associat

99 y between 1978 and 2007 at 4 US subspecialty uveitis centers.

100 ation was ascertained between any particular uveitis characteristic and extraocular sarcoidosis progr

101 normalities were related to demographics and uveitis characteristics, including anatomical classifica

102 This methodology could be useful for future uveitis classification and management.

103 reated with immunosuppressive therapy in the uveitis clinic at the Children's Medical Center, Dallas,

104 tly the most common diagnosis in series from uveitis clinics.

105 owed by a second instance of a noninfectious uveitis code within 120 days.

106 The uveitis cohort was further subdivided by the presence or

107 uveitic glaucoma/OHT and recurrent anterior uveitis compared with age-matched controls.

108 reduced risk of developing chronic recurrent uveitis compared with IMT given as clinically indicated.

109 ing follow-up, were similar in patients with uveitis compared with those without uveitis.

110 positive patients with otherwise unexplained uveitis completed antituberculous therapy (29/710; 4% of

111 ing vision among patients with noninfectious uveitis complicated by macular edema (ME).

112 Anterior uveitis complications (posterior synechiae and band kera

113 the factors that adult patients with chronic uveitis consider to be important when evaluating the imp

114 rada (VKH) disease which might indicate poor uveitis control in these patients.

115 Proper uveitis control is sufficient to achieve regression of r

116 Uveitis developed in 96 (22.1%) of 434 patients with JIA

117 ticosteroid injection within 120 days of the uveitis diagnosis code was used instead of the second uv

118 iagnosis code was used instead of the second uveitis diagnosis code.

119 , especially within the first 5 years of the uveitis diagnosis.

120 was conducted to record anatomic location of uveitis, disease activity, visual acuity, and treatments

121 In the absence of microglia, uveitis does not develop, since leukocytes cannot gain e

122 atrophy in 360 degrees secondary to anterior uveitis due to the coinfection of a virus and a parasite

123 otypic change during experimental autoimmune uveitis (EAU) development.

124 mice develop severe experimental autoimmune uveitis (EAU), an animal model of human uveitis.

125 In a rat model of experimental autoimmune uveitis (EAU), inflammation was significantly reduced in

126 the pathogenesis of experimental autoimmune uveitis (EAU).

127 to the induction of experimental autoimmune uveitis (EAU).

128 nd its animal model, experimental autoimmune uveitis (EAU).

129 erapeutic benefit in experimental autoimmune uveitis (EAU).

130 d four consecutive adults with noninfectious uveitis, enrolled between November 2016 and February 201

131 o uveitis events ("history"); no history and uveitis events ("first event"); history and uveitis even

132 veitis events ("no uveitis"); history and no uveitis events ("history"); no history and uveitis event

133 ng the observation period: no history and no uveitis events ("no uveitis"); history and no uveitis ev

134 uveitis events ("first event"); history and uveitis events ("recurrent event").

135 ed on the history of uveitis at baseline and uveitis events during the observation period: no history

136 ERGs of the total 355 uveitis eyes were measured according to an extended Inte

137 The uveitis features of QFT-G-positive patients were mainly

138 ed as a new diagnosis code for noninfectious uveitis followed by a second instance of a noninfectious

139 on model was trained to classify PVRL versus uveitis from aqueous and vitreous IL-6 and IL-10 samples

140 gnosis, and management of IOL decentrations, uveitis-glaucoma-hyphema (UGH) syndrome, IOL opacificati

141 The active uveitis group also showed lower median serum vitamin D l

142 ls were compared between active and inactive uveitis groups and with local population estimates.

143 s, were compared between active and inactive uveitis groups.

144 Patients with uveitis had a significantly shorter time to first relaps

145 ient cohort showed that patients with MS and uveitis had increased MS relapse activity compared with

146 Patients with noninfectious uveitis had measurable, though modest, reductions in qua

147 , the mouse model of experimental autoimmune uveitis has been employed to investigate disease mechani

148 Eyes with uveitis have significantly larger CC MFDS (3- x 3-mm sca

149 eriod: no history and no uveitis events ("no uveitis"); history and no uveitis events ("history"); no

150 n, the FHT cohort was more likely to develop uveitis (HR, 1.21; 95% CI, 1.04-1.41; P = 0.01).

151 FHT prescription were more likely to develop uveitis (HR, 1.23; 95% CI, 1.03-1.47; P = 0.03) for the

152 nt diagnosed brimonidine-associated anterior uveitis in a tertiary referral glaucoma clinic presentin

153 Exacerbated uveitis in CD19-STAT3KO mice derived in part from enhanc

154 an male patient with a diagnosis of anterior uveitis in his left eye due to varicella-zoster virus an

155 me sequencing can help diagnose nonsyndromic uveitis in patients harboring known variants for syndrom

156 logy and clinical features of viral anterior uveitis in patients in southern Taiwan.

157 s there was a greater likelihood of incident uveitis in the exposed cohort (HR, 1.23; 95% CI, 1.05-1.

158 ease, presenting with scleritis and anterior uveitis in the left eye, who experienced subsequent deve

159 as not been previously described in cases of uveitis in the literature.

160 FT-G tested positive in 13% of patients with uveitis in the Netherlands, whereas only sporadic patien

161 Uveitis in the pediatric population is uncommon, account

162 new modified protocols for inducing chronic uveitis in wild-type mice, and demonstrate a predominant

163 The most common diagnosis was intermediate uveitis, in 14 children (7 idiopathic, 7 pars planitis).

164 n exposure was associated significantly with uveitis inactivity (P = 0.014 for weekday and weekend an

165 ation also was associated significantly with uveitis inactivity (P = 0.026, Kendall's tau test).

166 Estimation of noninfectious uveitis incidence used multivariable Cox proportional ha

167 ve patients who all underwent evaluation for uveitis including QFT-G testing.

168 was measured serially for 35 days following uveitis induction.

169 in the general registry population (anterior uveitis IRR, 13.9; other uveitis IRR, 43.0; papilledema

170 opulation (anterior uveitis IRR, 13.9; other uveitis IRR, 43.0; papilledema IRR, 38.3).

171 Autoimmune uveitis is a sight-threatening intraocular inflammatory

172 Autoimmune uveitis is a sight-threatening ocular inflammatory condi

173 risk of progressing rapidly in glaucoma with uveitis is almost double than in those without uveitis.

174 This type of anterior uveitis is an uncommon but important manifestation which

175 A history of uveitis is associated with an increased risk of any degr

176 rate of incident noninfectious uveitis when uveitis is defined on the basis of both diagnostic codes

177 Idiopathic uveitis is frequently the most common diagnosis in serie

178 Cytomegalovirus anterior uveitis is not uncommon in patients in southern Taiwan,

179 2 and p = 0.03 respectively) while posterior uveitis manifestations (vitreous haze and vasculitis) we

180 Undifferentiated uveitis may be prone to premature discontinuation of ADA

181 Ocular WD in the form of uveitis may occur in the absence of systemic disease but

182 ased retinal thickness in chronic autoimmune uveitis mice, and electroretinography showed significant

183 ts from conventional experimental autoimmune uveitis models.

184 posterior uveitis (n = 5), and intermediate uveitis (n = 4).

185 (n = 9), anterior uveitis (n = 7), posterior uveitis (n = 5), and intermediate uveitis (n = 4).

186 r patterns were panuveitis (n = 9), anterior uveitis (n = 7), posterior uveitis (n = 5), and intermed

187 evel of serum vitamin D in those with active uveitis (n = 74) was 46 nmol/l (interquartile range [IQR

188 sion into several other indications, such as uveitis, neuromyelitis optica and, most recently, COVID-

189 lyze the incidence and risk of noninfectious uveitis (NIU) among postdelivery women with a history of

190 Non-infectious uveitis (NIU) is an intractable, recurrent, and painful

191 abetic macular edema, DME), or noninfectious uveitis (NIU).

192 Standardization of Uveitis Nomenclature (SUN) criteria were used to better

193 e identified according to Standardization of Uveitis Nomenclature Working Group criteria.

194 Uveitis occurred as a first event in 27 patients (incide

195 requently affected in cases of noninfectious uveitis of all anatomic subtypes, including anterior uve

196 164 patients with clinically diagnosed uveitis of the posterior segment.

197 The proportion of patients with uveitis of unknown etiology was higher in QFT-G-positive

198 Six eyes lacked anterior uveitis on initial or follow-up examination but had abno

199 stemic sarcoidosis was common at the time of uveitis onset.

200 e did not have any signs of anterior segment uveitis or iridocyclitis.

201 Patients with a history of uveitis or other ocular inflammatory condition demonstra

202 Among patients with posterior uveitis or panuveitis, treatment success was achieved in

203 of cataract formation independent of active uveitis or presence of posterior synechiae.

204 We reviewed all patients with uveitis or scleritis who subsequently developed pulmonar

205 (OR = 4.51), and "other" forms of posterior uveitis (OR = 16.9) were associated with a higher preval

206 involvement (intermediate uveitis, posterior uveitis, or panuveitis) was known or suspected, and whos

207 aqueous samples, 67 vitreous samples) and 84 uveitis patients (19 aqueous samples, 65 vitreous sample

208 Retrospective chart review of 80 eyes of 49 uveitis patients aged <=16 years.

209 d reduced LXA(4) levels in posterior segment uveitis patients and investigated the role of LXA(4) in

210 um 25-hydroxy vitamin D levels than inactive uveitis patients and local population-based estimates.

211 s were higher and IL-10 levels were lower in uveitis patients compared with lymphoma patients (P < 0.

212 Posterior uveitis patients have significantly larger CC FDs than p

213 A2Ar induction of PD-1(+)FoxP3(+) Tregs in uveitis patients was similar compared to healthy control

214 Twenty chronic uveitis patients were recruited to participate in two fo

215 be an important tool in evaluating pediatric uveitis patients with known or suspected posterior invol

216 01; 802 mum(2); P < .0001, respectively) and uveitis patients without choroidal involvement (785 mum(

217 Retrospective study of all uveitis patients, positive for RV in aqueous humor analy

218 A total of 205 eyes with diagnosis of uveitis plus glaucoma were compared with 4600 eyes with

219 posterior segment involvement (intermediate uveitis, posterior uveitis, or panuveitis) was known or

220 ata analysis and controlling for duration of uveitis, presence and degree of active uveitis, and conc

221 Other than uveitis (prevalence at enrollment, 26.4% vs. 12.1%; at y

222 Of these, 162 patients had a history of uveitis (prevalence, 0.59%).

223 duration of uveitis, younger age, bilateral uveitis, prior cataract surgery, glaucoma surgery, prese

224 Uveitis recurred in 55.7% of all eyes.

225 nsert-treated eyes had significantly reduced uveitis recurrence rates throughout the study duration,

226 nth (28% and 91%) and 12-month (38% and 98%) uveitis recurrence rates were significantly lower (P < 0

227 Uveitis recurrence was treated as needed.

228 -treated and sham-treated patients who had a uveitis recurrence.

229 Over 36 months of treatment, cumulative uveitis recurrences were significantly reduced with FAi

230 e studied as an option for the prevention of uveitis relapse in at-risk patients.

231 Underlying diseases associated with uveitis-related CME are juvenile idiopathic arthritis (n

232 ollowing administration of TCZ in refractory uveitis-related CME.

233 mechanisms by which dysregulated Nod2 causes uveitis remain unknown.

234 one third of patients with chronic anterior uveitis remit within 5 years.

235 trial screened 265 adults with noninfectious uveitis requiring corticosteroid-sparing immunosuppressi

236 Patients with noninfectious uveitis requiring immunosuppressive therapy, in which po

237 Uveitis resolved in 24 of 58 eyes (41.4%), became chroni

238 with optic disc edema, often associated with uveitis, retinitis, or both.

239 sly-associated with non-infectious posterior uveitis, rhegmatogenous retinal detachment (RRD), age-re

240 is likely safe with regard to noninfectious uveitis risk in the majority of patients exposed to thes

241 Our results suggest that uveitis screening should start immediately when the diag

242 Anterior uveitis secondary to topical brimonidine administration

243 are ophthalmological finding associated with uveitis secondary to varicella-zoster virus and Toxoplas

244 uding anatomical classification, duration of uveitis, severity of inflammation, best corrected visual

245 Participants with active uveitis showed significantly lower serum 25-hydroxy vita

246 can contribute to the development of future uveitis specific measures in adults.

247 l Ocular Inflammation Society, International Uveitis Study Group, and Foster Ocular Immunological Soc

248 r Inflammation Society and the International Uveitis Study Group, systematically developed evidence-

249 from 38 control subjects and 73 eyes from 73 uveitis subjects were included in this study.

250 ly implicated in specific types of syndromic uveitis-such as NOD2 (Blau syndrome) and CAPN5 NIV (neov

251 hat may be associated with posterior segment uveitis susceptibility.

252 Tubulointerstitial nephritis and uveitis syndrome is under-recognized in the clinical set

253 Tubulointerstitial nephritis and uveitis syndrome should be considered in the differentia

254 324 questions related to tubercular anterior uveitis (TAU), tubercular intermediate uveitis (TIU), tu

255 The diagnosis and management of tubercular uveitis (TBU) pose a significant challenge.

256 guidelines for the management of tubercular uveitis (TBU).

257 loss occurs faster in glaucoma patients with uveitis than those without uveitis.

258 Incidence rates for anterior uveitis, the most common ophthalmic immune-related AE, w

259 have been studied extensively in autoimmune uveitis, their exact function remains uncertain.

260 n examined by anatomic subtype, for anterior uveitis there was a greater likelihood of incident uveit

261 With the exception of uveitis, these conditions declined in prevalence during

262 erior uveitis (TAU), tubercular intermediate uveitis (TIU), tubercular panuveitis (TPU), and tubercul

263 venile idiopathic arthritis (JIA)-associated uveitis treated with topical corticosteroids.

264 2); whereas among patients with intermediate uveitis treatment success occurred in 6 (33.3%) in the m

265 abolites as Steroid-sparing Treatment (FAST) uveitis trial screened 265 adults with noninfectious uve

266 of juvenile idiopathic arthritis associated uveitis) trial (identifier, ISRCTN10065623) of methotrex

267 MT) and with historical data (IMT added when uveitis uncontrolled).

268 Chronic anterior uveitis, vitritis, early development of cataract, and th

269 due to inefficacy," whereas undifferentiated uveitis was a predictor for "discontinuation due to adve

270 etween the onset of JIA and the diagnosis of uveitis was a risk factor for developing ocular complica

271 Uveitis was active at ME diagnosis in 28 eyes (84.8%).

272 the primary outcome, incident noninfectious uveitis was defined as a new diagnosis code for noninfec

273 ust and reliable model of chronic autoimmune uveitis was developed and characterized in two strains o

274 In 12 patients (2.8%), uveitis was diagnosed between 8 and 18 years of follow-u

275 The proportion of patients with unexplained uveitis was higher in QFT-G-positive patients.

276 Prevalence of uveitis was highest in northern Europe (161 [19.1%] of 8

277 A history of uveitis was identified in 5.4% of eyes.

278 In the analysis of a PVR subgroup, uveitis was not associated with a higher risk of PVR nec

279 hazard ratio (HR) for incident noninfectious uveitis was not significantly different between the FHT

280 Active uveitis was present in 19 of 78 patients (24.4%) at the

281 Nonanterior uveitis was recorded in 242 patients.

282 ation to resolution of stromal keratitis and uveitis was significantly shorter in the steroid group c

283 Idiopathic uveitis was the most common diagnosis (51%).

284 pants with recurrent noninfectious posterior uveitis were assigned randomly to FA insert (n = 87) or

285 eyes of 1634 patients with chronic anterior uveitis were followed up over 7936 eye-years (4676 perso

286 Eyes with a history of uveitis were found to have a higher risk for development

287 However, clinical trials targeting IL-17A in uveitis were not successful.

288 ients with active and inactive noninfectious uveitis were recruited from 2 Victorian tertiary hospita

289 increases the rate of incident noninfectious uveitis when uveitis is defined on the basis of both dia

290 , with loss of STAT3 in B cells exacerbating uveitis whereas Stat3 deletion in T cells confers protec

291 analysis, remission was defined as inactive uveitis while off treatment at all visits spanning an in

292 sis suggests that patients with a history of uveitis who develop PVR do not necessarily have a worse

293 Patients with CME secondary to noninfectious uveitis who had inadequate response to corticosteroids a

294 ative steroids in patients with a history of uveitis who present with a retinal detachment, but furth

295 All patients with noninfectious uveitis who were switched from the originator infliximab

296 d protocols resulted in a slowly progressive uveitis, with retinal scars and atrophy observed in the

297 of all anatomic subtypes, including anterior uveitis without apparent inflammation of the posterior s

298 nosis for patients presenting with bilateral uveitis without evidence of infection or other clear eti

299 ree of 17 patients (18%) showed retinitis or uveitis without optic neuropathy.

300 Longer duration of uveitis, younger age, bilateral uveitis, prior cataract